Lacosamide is a novel antiepileptic drug approved as adjunctive treatment of refractorypartial-onset epilepsy in patients 17 years of age or older.1 Lacosamide is a functionalized amino acid compound that, in adults, has 100% oral absorption with linear pharmacokinetics, low protein binding (<19%), peak blood concentration in 1 to 2 hours with a 13-hour half-life, renal clearance, limited hepatic metabolism, and no known significant drug interactions.2 Considering the encouraging pharmacokinetics, lacosamide should be a favorable option for treatment in children as well. Lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels.3 Sodium channels are responsible for the generation and propagation of nerve action potentials and control of overall neuronal excitability. Lacosamide action on the slow inactivation of the voltage-gated sodium channel is a new area of attack on an ion channel
การแปล กรุณารอสักครู่..